Table 1.

Font trial: demographic and clinical features of the subject Cohort

		Age at consent	Age at consent
	Overall (N = 21)	<18 years (N = 14)	≥18 years (N = 7)
	N (%) or Median (IQR)	N (%) or Median (IQR)	N (%) or Median (IQR)
Age at Consent (yr)	14.7 (13.0, 20.8)	13.5 (12.8, 14.7)	28.6 (20.8, 34.0)
Female	12 (57.1 %)	8 (57.1 %)	4 (57.1 %)
Race (self-reported)
Black or African American	4 (19.0 %)	2 (14.3 %)	2 (28.6 %)
White	12 (57.1 %)	7 (50.0 %)	5 (71.4 %)
More than one race	1 (4.8 %)	1 (7.1 %)
Unknown	4 (19.0 %)	4 (28.6 %)
Ethnicity (Self-reported)	7 (33.3 %)	6 (42.9 %)	1 (14.3 %)
Sitting Systolic BP	109 (104, 120)	109 (88.0, 115)	126 (107, 129)
Sitting Diastolic BP	66.0 (60.0, 74.0)	62.5 (54.0, 71.0)	74.0 (68.0, 79.0)
Previous Rx with Cyclosporine	12 (57.1 %)	6 (42.9 %)	6 (85.7 %)
Cyclosporine Rx: Cumulative Exposure (mos)	6.00 (5.50, 12.0)	5.50 (4.00, 12.0)	6.00 (6.00, 12.0)
Previous Rx with Tacrolimus	13 (61.9 %)	8 (57.1 %)	5 (71.4 %)
Tacrolimus Rx: Cumulative Exposure (mos)	7.00 (4.00, 24.0)	9.50 (4.00, 31.0)	6.00 (6.00, 24.0)
Previous Rx with Mycophenolate	11 (52.4 %)	9 (64.3 %)	2 (28.6 %)
Mycophenolate Rx: Cumulative Exposure (mos)	6.00 (4.00, 17.0)	6.00 (5.00, 12.0)	9.50 (1.00, 18.0)
Edema
None	14 (66.7 %)	9 (64.3 %)	5 (71.4 %)
Pretibial	6 (28.6 %)	4 (28.6 %)	2 (28.6 %)
Ascites	1 (4.8 %)	1 (7.1 %)	0 (0 %)
Serum Albumin (g/dL) at Screening	2.40 (2.10, 3.50)	2.40 (2.05, 3.60)	2.50 (2.10, 3.50)
Total Cholesterol (mg/dL) at Screening	276 (198, 424)	297 (163, 452)	267 (198, 424)
Up/c at Screening	4.93 (3.30, 11.5)	9.28 (3.30, 12.2)	3.41 (3.23, 4.93)
Baseline eGFR (ml/min/1.73 m2)	120 (81.1, 170)	119 (88.2, 221)	120 (71.5, 151)
Duration of Follow up Post Randomization (yr)	1.63 (1.27, 1.74)	1.66 (1.48, 2.03)	1.24 (1.06, 1.70)

Note: Excludes the subject randomized to Rosiglitazone